Whitney Ijem

Whitney Ijem is SVP, Strategy and Business Development at Krystal. Before Krystal, she was a Managing Director and Senior Biotechnology Analyst covering genetic medicine and rare disease companies at Guggenheim Securities. Prior to Joining Guggenheim, Ms. Ijem was a therapeutics analyst at Tourbillon Capital where she focused on companies across the therapeutics space. Prior to Tourbillon, she was an analyst in the J.P. Morgan Equity Research Healthcare group focused on biotechnology. Before joining J.P. Morgan, Ms. Ijem was a biotech analyst at Canaccord Genuity. She holds a B.S. in Biomedical Engineering from Washington University in St. Louis and a M.S. in Biomaterials Science from New York University.